These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26481083)

  • 1. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.
    Lonn E; Bosch J; Pogue J; Avezum A; Chazova I; Dans A; Diaz R; Fodor GJ; Held C; Jansky P; Keltai M; Keltai K; Kunti K; Kim JH; Leiter L; Lewis B; Liu L; Lopez-Jaramillo P; Pais P; Parkhomenko A; Peters RJ; Piegas LS; Reid CM; Sliwa K; Toff WD; Varigos J; Xavier D; Yusoff K; Zhu J; Dagenais G; Yusuf S;
    Can J Cardiol; 2016 Mar; 32(3):311-8. PubMed ID: 26481083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
    Yusuf S; Lonn E; Pais P; Bosch J; López-Jaramillo P; Zhu J; Xavier D; Avezum A; Leiter LA; Piegas LS; Parkhomenko A; Keltai M; Keltai K; Sliwa K; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Accini JL; McKelvie R; Pogue J; Jung H; Liu L; Diaz R; Dans A; Dagenais G;
    N Engl J Med; 2016 May; 374(21):2032-43. PubMed ID: 27039945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
    Lonn EM; Bosch J; López-Jaramillo P; Zhu J; Liu L; Pais P; Diaz R; Xavier D; Sliwa K; Dans A; Avezum A; Piegas LS; Keltai K; Keltai M; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Parkhomenko A; Khunti K; Toff WD; Reid CM; Varigos J; Leiter LA; Molina DI; McKelvie R; Pogue J; Wilkinson J; Jung H; Dagenais G; Yusuf S;
    N Engl J Med; 2016 May; 374(21):2009-20. PubMed ID: 27041480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3.
    Waters DD; Chau KH
    Can J Cardiol; 2016 Mar; 32(3):275-7. PubMed ID: 26577896
    [No Abstract]   [Full Text] [Related]  

  • 5. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
    Yusuf S; Bosch J; Dagenais G; Zhu J; Xavier D; Liu L; Pais P; López-Jaramillo P; Leiter LA; Dans A; Avezum A; Piegas LS; Parkhomenko A; Keltai K; Keltai M; Sliwa K; Peters RJ; Held C; Chazova I; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Sanchez-Vallejo G; McKelvie R; Pogue J; Jung H; Gao P; Diaz R; Lonn E;
    N Engl J Med; 2016 May; 374(21):2021-31. PubMed ID: 27040132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost implication of primary prevention in the HOPE 3 trial.
    Lamy A; Lonn E; Tong W; Swaminathan B; Jung H; Gafni A; Bosch J; Yusuf S
    Eur Heart J Qual Care Clin Outcomes; 2019 Jul; 5(3):266-271. PubMed ID: 30657891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial.
    Joseph P; Lonn E; Bosch J; Lopez P; Zhu J; Keltai M; Dans A; Reid C; Khunti K; Toff W; Piegas L; Kim JH; Swaminathan B; Bohm M; Yusuf S;
    Can J Cardiol; 2018 Jan; 34(1):38-44. PubMed ID: 29275880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
    Pais P; Jung H; Dans A; Zhu J; Liu L; Kamath D; Bosch J; Lonn E; Yusuf S
    Eur J Prev Cardiol; 2019 May; 26(7):681-697. PubMed ID: 30537846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial.
    Dagenais GR; Jung H; Lonn E; Bogaty PM; Dehghan M; Held C; Avezum A; Jansky P; Keltai M; Leiter LA; Lopez-Jaramillo P; Toff WD; Bosch J; Yusuf S
    J Am Heart Assoc; 2018 Jul; 7(15):. PubMed ID: 30033433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.
    Bosch J; O'Donnell M; Swaminathan B; Lonn EM; Sharma M; Dagenais G; Diaz R; Khunti K; Lewis BS; Avezum A; Held C; Keltai M; Reid C; Toff WD; Dans A; Leiter LA; Sliwa K; Lee SF; Pogue JM; Hart R; Yusuf S;
    Neurology; 2019 Mar; 92(13):e1435-e1446. PubMed ID: 30814321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
    Bosch J; Lonn EM; Jung H; Zhu J; Liu L; Lopez-Jaramillo P; Pais P; Xavier D; Diaz R; Dagenais G; Dans A; Avezum A; Piegas LS; Parkhomenko A; Keltai K; Keltai M; Sliwa K; Held C; Peters RJG; Lewis BS; Jansky P; Yusoff K; Khunti K; Toff WD; Reid CM; Varigos J; Joseph P; Leiter LA; Yusuf S
    Eur Heart J; 2021 Aug; 42(31):2995-3007. PubMed ID: 33963372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
    Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
    J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
    Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
    JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
    Nakamura T; Kanno Y; Takenaka T; Suzuki H;
    Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
    Joseph P; Pais P; Dans AL; Bosch J; Xavier D; Lopez-Jaramillo P; Yusoff K; Santoso A; Talukder S; Gamra H; Yeates K; Lopez PC; Tyrwhitt J; Gao P; Teo K; Yusuf S;
    Am Heart J; 2018 Dec; 206():72-79. PubMed ID: 30342297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
    N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.